/logo-16545883420.png){kind=logo}
Shenogen Shandong Industrial Base Selected as 2014 Shandong Key Projects
Apr 22nd, Beijing, China
Shandong province government announces that Shenogen Shandong Industrial Base Project is on the name list of 2014 Shandong Key Projects. This project was started in Laiwu, Shandong, at the beginning of 2012 with total investment 7 billion RMB. It is owned by Beijing Shenogen Biomedical Co., Ltd. and is built for industrialization of Icaritin. The output value is expected to reach 70 billion RMB per year at full capacity. This project is regarded as a driving power for biopharma development in Laiwu.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.